0001104659-13-059256.txt : 20130802 0001104659-13-059256.hdr.sgml : 20130802 20130802111331 ACCESSION NUMBER: 0001104659-13-059256 CONFORMED SUBMISSION TYPE: SC TO-C PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20130802 DATE AS OF CHANGE: 20130802 GROUP MEMBERS: BRGO CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Trius Therapeutics Inc CENTRAL INDEX KEY: 0001356857 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201320630 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-C SEC ACT: 1934 Act SEC FILE NUMBER: 005-85614 FILM NUMBER: 131005241 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DR SUITE 105 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-452-0370 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DR SUITE 105 CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CUBIST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000912183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223192085 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-C BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-860-8660 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 SC TO-C 1 a13-17558_8sctoc.htm SC TO-C

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT

 

UNDER

SECTION 14(D)(1) OR SECTION 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

TRIUS THERAPEUTICS, INC.

(Name Of Subject Company (Issuer))

 

BRGO CORPORATION

CUBIST PHARMACEUTICALS, INC.

(Names of Filing Persons (Offerors))

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

89685K100

(CUSIP Number of Common Stock)

 

 

Thomas J. DesRosier

Senior Vice President, Chief Legal Officer,

General Counsel and Secretary

Cubist Pharmaceuticals, Inc.

65 Hayden Avenue

Lexington, MA 02421

(781) 860-8660

(Name, address and telephone number of person authorized

to receive notices and communications on behalf of filing persons)

 

 

with copies to:

Christopher Comeau

Paul Kinsella

Ropes & Gray LLP

800 Boylston Street

Boston, Massachusetts 02199

Telephone: (617) 951-7000

 

CALCULATION OF FILING FEE

 

Transaction Valuation

 

Amount Of Filing Fee

Not Applicable*

 

Not Applicable*

 

*                 A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.

 

o            Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

 

Amount Previously Paid:

 

N/A

 

Form or Registration No.:

 

N/A

 

Filing Party:

 

N/A

 

Date Filed:

 

N/A

 

 

x          Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

Check the appropriate boxes below to designate any transactions to which the statement relates:

x                third-party tender offer subject to Rule 14d-1.

o                  issuer tender offer subject to Rule 13e-4.

o                  going-private transaction subject to Rule 13e-3.

o                  amendment to Schedule 13D under Rule 13d-2.

 

Check the following box if the filing is a final amendment reporting the results of the tender offer:  o

 

 

 


 

ITEM  12.                        EXHIBITS

 

Exhibit
No.

 

Description

99.1

 

Form of communication to infectious disease experts

 

2

 EX-99.1 2 a13-17558_8ex99d1.htm EX-99.1

 

Date

 

Dear Dr. XXX;

 

Earlier this week, Cubist announced our planned acquisitions of both Trius Therapeutics and Optimer Pharmaceuticals.  As a key infectious disease expert, we thought it important to convey this information to you directly.

 

The prospects of continuing the development and potential commercialization of tedizolid (Trius) and the marketing of DIFICID (Optimer) reaffirms Cubist’s mission to provide therapies for seriously ill patients treated in and around the hospital setting.

 

Assuming the successful completion of the planned acquisitions and the success of our combined late stage pipeline, Cubist will contribute significantly towards the goal set by IDSA in their “10 by ’20” program for 2020.

 

We are excited about building the Cubist infectious disease portfolio and look forward to meeting with you soon.

 

Sincerely;

 

Lorianne K. Masuoka, M.D.

Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer

 

Peggy McKinnon, PharmD

Sr. Director, Field Medical Affairs

 

Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, MA  02421